Study S000005

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07091734
Acronym: TILT-2024
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 32
Start: 2025-09-08
Primary completion: 2029-09
Lead sponsor: University of Michigan
Conditions: Lipodystrophy, Partial
Interventions: DRUG:Tirzepatide; DRUG:Usual care medications
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change in Body Mass Index (BMI) from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks [Baseline, 24 weeks]
Change in Hemoglobin A1c from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks [Baseline, 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.